Marker Therapeutics Proxy Statement Filed for June 6 Meeting
Ticker: MRKR · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Marker Therapeutics DEF 14A filed, proxy vote coming up June 6. Vote wisely.
AI Summary
Marker Therapeutics, Inc. filed its definitive proxy statement on April 24, 2025, for its annual meeting on June 6, 2025. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other shareholder proposals.
Why It Matters
This filing provides crucial information for shareholders to make informed decisions regarding the company's leadership and strategic direction, impacting potential future stock performance.
Risk Assessment
Risk Level: medium — Proxy statements often contain information about executive compensation, board composition, and shareholder proposals that can signal potential changes in company strategy or governance, which may affect investor sentiment.
Key Numbers
- 20 — Document Count (Indicates the number of documents included in the filing.)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former Company Name
- GENEMAX CORP (company) — Former Company Name
- 20250424 (date) — Filing Date
- 20250606 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting scheduled for June 6, 2025, covering matters such as director elections and executive compensation.
When was this proxy statement filed with the SEC?
This definitive proxy statement was filed on April 24, 2025.
What are the former names of Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. and GENEMAX CORP.
Where is Marker Therapeutics, Inc. headquartered?
Marker Therapeutics, Inc. is headquartered in Houston, Texas, with its business address at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, TX 77021.
What is the standard industrial classification for Marker Therapeutics, Inc.?
The standard industrial classification for Marker Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Marker Therapeutics, Inc. (MRKR).